Abstract:Objective To investigate the trend in disease burden of asthma attributable to tobacco in China from 1990 to 2021, so as to provide the basis for improving intervention measures of asthma. Methods Data on asthma-related mortality and disability-adjusted life years (DALY) attributable to tobacco among adults aged ≥30 years in China from 1990 to 2021 were collected from the Global Burden of Disease (GBD) 2021 database. Age-standardized mortality and age-standardized DALY rate were calculated using the GBD world standard population structure to analyze the tobacco-attributable asthma burden. The average annual percent change (AAPC) was employed to evaluate temporal trends in the age-standardized mortality and DALY rate from 1990 to 2021. Results In China, the age-standardized mortality and age-standardized DALY rate of asthma attributable to tobacco decreased from 0.73/105 and 22.20/105 in 1990 to 0.17/105 and 6.64/105 in 2021, showing downward trends (AAPC=-4.603% and -3.888%, both P<0.05). Among males, the tobacco-attributable age-standardized mortality and age-standardized DALY rate declined from 1.44/105 and 41.05/105 in 1990 to 0.36/105 and 12.79/105 in 2021 (AAPC=-4.369% and -3.810%, both P<0.05). Among females, the corresponding rates decreased from 0.21/105 and 5.37/105 to 0.03/105 and 1.08/105 (AAPC=-6.074% and -5.074%, both P<0.05). In 2021, males had higher tobacco-attributable age-standardized mortality and age-standardized DALY rate for asthma than females. Both the mortality and DALY rate of asthma attributable to tobacco increased with age, peaking in the age group ≥80 years at 7.84/105 and 112.07/105, respectively. Conclusion From 1990 to 2021, the disease burden of asthma attributable to tobacco showed a declining trend in China, with males and elderly population aged ≥80 years bearing a relatively heavier disease burden.
马荣娇, 黄涵焱, 朱镘羽, 刘瑞, 石芳. 1990—2021年中国归因于烟草的哮喘疾病负担趋势分析[J]. 预防医学, 2026, 38(1): 89-92.
MA Rongjiao, HUANG Hanyan, ZHU Manyu, LIU Rui, SHI Fang. Trend in disease burden of asthma attributable to tobacco in China from 1990 to 2021. Preventive Medicine, 2026, 38(1): 89-92.
[1] HUANG K W,YANG T,XU J Y,et al.Prevalence,risk factors,and management of asthma in China:a national cross-sectional study[J].Lancet,2019,394(10196):407-418. [2] 柏海蓉,柴培培,赵燕,等.1990—2021年我国哮喘疾病负担变化及趋势分析[J].中国卫生经济,2024,43(12):43-46. [3] YUAN L N,TAO J X,WANG J C,et al.Global,regional,national burden of asthma from 1990 to 2021,with projections of incidence to 2050:a systematic analysis of the global burden of disease study 2021[J/OL].EClinicalMedicine,2025,80[2025-11-24].https://doi.org/10.1016/j.eclinm.2024.103051. [4] 王寅丹,李婷,张国庆,等.电子烟急性暴露对小鼠BALF及肺表面活性蛋白的影响研究[J].预防医学,2022,34(5):456-460. [5] THOMSON N C,POLOSA R,SIN D D.Cigarette smoking and asthma[J].J Allergy Clin Immunol Pract,2022,10(11):2783-2797. [6] 中国疾病预防控制中心.2018年中国成人烟草调查报告[R].北京:中国疾病预防控制中心,2019. [7] GBD 2021 Causes of Death Collaborators.Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations,1990-2021:a systematic analysis for the Global Burden of Disease Study 2021[J].Lancet,2024,403(10440):2100-2132. [8] LV B,LAN J X,SI Y F,et al.Epidemiological trends of subarachnoid hemorrhage at global,regional,and national level:a trend analysis study from1990 to 2021[J/OL].Mil Med Res,2024,11(1)[2025-11-24].https://doi.org/10.1186/s40779-024-00551-6. [9] CHAN K H,XIAO D,ZHOU M G,et al.Tobacco control in China[J].Lancet Public Health,2023,8(12):1006-1015. [10] 陈泓君,尹慧.中国城市无烟立法的综合影响[J].中国健康教育,2025,41(5):451-458. [11] YANG G H,WANG Y,WU Y Q,et al.The road to effective tobacco control in China[J].Lancet,2015,385(9972):1019-1028. [12] FAZEL N,KUNDI M,KAZEMZADEH A,et al.Environmental tobacco smoke exposure during pregnancy affects complications and birth outcomes in women with and without asthma[J/OL].BMC Pregnancy Childbirth,2020,20(1)[2025-11-24].https://doi.org/10.1186/s12884-020-03000-z. [13] 王辰,肖丹,池慧.《中国吸烟危害健康报告2020》概要[J].中国循环杂志,2021,36(10):937-952. [14] PERPIÑÁ TORDERA M,ÁLVAREZ GUTIÉRREZ F J,BLANCO APARICIO M.Asthma exists in older people too[J].Arch Bronconeumol,2022,58(5):390-391. [15] TOMASELLO A,BENFANTE A,LISOTTA A,et al.Polypharmacy in older patients with asthma:hidden risks and opportunities for improvement[J].Expert Rev Respir Med,2024,18(12):1047-1059. [16] 江璇,刘新宇,李恩亮,等.针挑疗法联合人参胡桃汤对支气管哮喘老年患者血清CCR5、Eotaxin水平及免疫Th17、Treg细胞平衡的影响[J].中国老年学杂志,2024,44(17):4123-4127.